Image source: OnlyMyHealth
Since the World Health Organisation (WHO) announced monkeypox to be the second public health emergency of international concern, India has developed an indigenous RT-PCR testing kit to fight the disease. This virus’s new strain, known as Clad-1, is more transmissible and has a higher death rate.
The Central Drugs Standard Control Organisation has approved Siemens Healthineers’ IMDX Monkeypox Detection RT-PCR Assay for manufacturing.
Test results, according to Siemens Healthcare Private Ltd., would be available in about forty minutes—much faster than with existing procedures, which take one to two hours. The test allows quicker responses by reducing the reporting turnaround time.
The ICMR-National Institute of Virology, Pune, has clinically validated the IMDX Monkeypox RTPCR Assay kits, which have an amazing 100% sensitivity and specificity. The kits meet the highest international standards as well as Indian statutory guidelines.
The managing director of Siemens Healthcare Private Limited, Hariharan Subramanian, emphasized the significance of precise and accurate diagnostics in the current situation. “By providing India with advanced assay kits tailored to combat Monkeypox, we are taking a proactive stance in battling this disease and prioritising prompt and precise detection that can truly make a difference in saving lives. These kits are a testament to our focus on improving ‘Access to Care’ and these assay kits are a significant step towards that goal.”
